JP5766124B2 - 炎症性疾患および自己免疫疾患の処置の組成物および方法 - Google Patents

炎症性疾患および自己免疫疾患の処置の組成物および方法 Download PDF

Info

Publication number
JP5766124B2
JP5766124B2 JP2011548074A JP2011548074A JP5766124B2 JP 5766124 B2 JP5766124 B2 JP 5766124B2 JP 2011548074 A JP2011548074 A JP 2011548074A JP 2011548074 A JP2011548074 A JP 2011548074A JP 5766124 B2 JP5766124 B2 JP 5766124B2
Authority
JP
Japan
Prior art keywords
seq
variant
cells
set forth
foxp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011548074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515778A (ja
JP2012515778A5 (enExample
Inventor
マーク エー． ギャビン，
マーク エー． ギャビン，
リー リー，
リー リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42356180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5766124(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2012515778A publication Critical patent/JP2012515778A/ja
Publication of JP2012515778A5 publication Critical patent/JP2012515778A5/ja
Application granted granted Critical
Publication of JP5766124B2 publication Critical patent/JP5766124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011548074A 2009-01-21 2010-01-20 炎症性疾患および自己免疫疾患の処置の組成物および方法 Active JP5766124B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14611109P 2009-01-21 2009-01-21
US61/146,111 2009-01-21
PCT/US2010/021519 WO2010085495A1 (en) 2009-01-21 2010-01-20 Compositions and methods of treating inflammatory and autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014083388A Division JP2014133756A (ja) 2009-01-21 2014-04-15 炎症性疾患および自己免疫疾患の処置の組成物および方法

Publications (3)

Publication Number Publication Date
JP2012515778A JP2012515778A (ja) 2012-07-12
JP2012515778A5 JP2012515778A5 (enExample) 2013-02-14
JP5766124B2 true JP5766124B2 (ja) 2015-08-19

Family

ID=42356180

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011548074A Active JP5766124B2 (ja) 2009-01-21 2010-01-20 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2014083388A Withdrawn JP2014133756A (ja) 2009-01-21 2014-04-15 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2016092985A Withdrawn JP2016138140A (ja) 2009-01-21 2016-05-06 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2018031926A Withdrawn JP2018087244A (ja) 2009-01-21 2018-02-26 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2019191112A Withdrawn JP2020023550A (ja) 2009-01-21 2019-10-18 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2021143804A Withdrawn JP2021185191A (ja) 2009-01-21 2021-09-03 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2024085664A Pending JP2024105721A (ja) 2009-01-21 2024-05-27 炎症性疾患および自己免疫疾患の処置の組成物および方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014083388A Withdrawn JP2014133756A (ja) 2009-01-21 2014-04-15 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2016092985A Withdrawn JP2016138140A (ja) 2009-01-21 2016-05-06 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2018031926A Withdrawn JP2018087244A (ja) 2009-01-21 2018-02-26 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2019191112A Withdrawn JP2020023550A (ja) 2009-01-21 2019-10-18 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2021143804A Withdrawn JP2021185191A (ja) 2009-01-21 2021-09-03 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2024085664A Pending JP2024105721A (ja) 2009-01-21 2024-05-27 炎症性疾患および自己免疫疾患の処置の組成物および方法

Country Status (8)

Country Link
US (5) US20110274650A1 (enExample)
EP (1) EP2382228B1 (enExample)
JP (7) JP5766124B2 (enExample)
AU (1) AU2010206840B2 (enExample)
CA (1) CA2749539C (enExample)
ES (1) ES2825173T3 (enExample)
MX (1) MX2011007647A (enExample)
WO (1) WO2010085495A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11945852B2 (en) 2017-12-06 2024-04-02 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
MX347324B (es) * 2011-03-11 2017-04-19 Assist Publique-Hôpitaux De Paris Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
BR112013023151A2 (pt) * 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9481866B2 (en) * 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
SI3102595T1 (sl) * 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
US10150802B2 (en) * 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR102493543B1 (ko) * 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
CA2982362A1 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20250133490A (ko) * 2016-05-04 2025-09-05 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
EP3641814A4 (en) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス，インク． 非天然ヌクレオチドの組み込み及びその方法
BR112020002272A2 (pt) * 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
AU2018328283A1 (en) * 2017-09-07 2020-02-20 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
WO2019131964A1 (ja) * 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
EP3762406A2 (en) 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
JP7636323B2 (ja) 2018-11-08 2025-02-26 シンソークス， インコーポレイテッド インターロイキン１０コンジュゲートおよびその使用
KR20210107714A (ko) 2018-12-21 2021-09-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인터류킨-2 변이체 또는 이의 유도체
CN113660946A (zh) 2019-02-06 2021-11-16 新索思股份有限公司 Il-2缀合物及其使用方法
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
AU2020252119B2 (en) * 2019-03-29 2025-09-04 Centre National De La Recherche Scientifique - Cnrs Interleukin-2 variants with modified biological activity
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
AU2020291012B2 (en) 2019-06-12 2025-09-25 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
AU2020328038B2 (en) 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
AU2020329933A1 (en) * 2019-08-15 2022-03-24 Cytimm Therapeutics, Inc. Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
AU2020337869A1 (en) 2019-08-23 2022-03-03 Synthorx, Inc. IL-15 conjugates and uses thereof
JP7758662B2 (ja) 2019-09-10 2025-10-22 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび自己免疫疾患を治療するための使用方法
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP2023514010A (ja) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－２ポリペプチドおよびその使用
EP4090354A4 (en) * 2020-01-14 2024-05-22 Synthekine, Inc. IL2 MUTEINS
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
TW202203973A (zh) 2020-04-22 2022-02-01 美商默沙東藥廠 對介白素-2受體βγc二聚體具偏性且結合至非肽、水溶性聚合物之人類介白素-2結合物
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
JP2023533567A (ja) * 2020-07-14 2023-08-03 ファイザー・インク 組み換えワクシニアウイルス
WO2022043493A1 (en) * 2020-08-28 2022-03-03 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
MX2023005030A (es) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Proteinas de fusion para el tratamiento de enfermedades.
CN112279906B (zh) * 2020-10-30 2022-09-20 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其制备方法与应用
CA3201446A1 (en) 2020-11-13 2022-05-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
CN113321722A (zh) * 2021-04-13 2021-08-31 苏州复融生物技术有限公司 白介素2突变体及其应用
WO2023281483A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified tnf-antibodies and uses thereof
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
JP7618848B2 (ja) 2021-07-30 2025-01-21 ドラコターピン バイオメディスン エルエルシー ヒトインターロイキン－２変異体およびその使用
MX2024004291A (es) 2021-10-06 2024-06-28 Iltoo Pharma Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025221954A1 (en) 2024-04-17 2025-10-23 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470461A (en) 1982-09-30 1984-09-11 Phillips Petroleum Company Organic nitro compounds as cosurfactants in enhanced oil recovery processes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0262802A3 (en) 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
EP0378666A4 (en) 1988-07-05 1992-01-22 Amgen Inc. Interleukin ii analogs
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
JP2005507870A (ja) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−２突然変異体
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AR043504A1 (es) 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CA2557677A1 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2006232374B2 (en) * 2005-04-01 2011-08-25 University Of Southern California Preventing rejection of transplanted tissue using regulatory T cells
AU2007214426A1 (en) 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
CN101479570A (zh) 2006-07-06 2009-07-08 三菱电机株式会社 导航装置
WO2008112325A2 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
CA2679399A1 (en) 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010017220A1 (en) 2008-08-04 2010-02-11 The Trustees Of The University Of Pennsylvania Methods for expanding regulatory t-cells
KR101094207B1 (ko) 2008-08-21 2011-12-14 연세대학교 산학협력단 Ｔ１―ｔ２ 이중방식 ｍｒｉ 조영제
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
MX347324B (es) 2011-03-11 2017-04-19 Assist Publique-Hôpitaux De Paris Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11945852B2 (en) 2017-12-06 2024-04-02 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
US12297249B2 (en) 2019-07-26 2025-05-13 Visterra, Inc. Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Also Published As

Publication number Publication date
US20250270271A1 (en) 2025-08-28
US11560415B2 (en) 2023-01-24
JP2024105721A (ja) 2024-08-06
JP2018087244A (ja) 2018-06-07
CA2749539C (en) 2022-07-19
EP2382228A4 (en) 2013-01-09
US20110274650A1 (en) 2011-11-10
US20170313753A1 (en) 2017-11-02
EP2382228B1 (en) 2020-08-26
US20230139534A1 (en) 2023-05-04
MX2011007647A (es) 2011-09-01
JP2012515778A (ja) 2012-07-12
JP2014133756A (ja) 2014-07-24
JP2020023550A (ja) 2020-02-13
ES2825173T3 (es) 2021-05-14
US20130195795A1 (en) 2013-08-01
EP2382228A1 (en) 2011-11-02
US9732134B2 (en) 2017-08-15
US12297248B2 (en) 2025-05-13
WO2010085495A1 (en) 2010-07-29
CA2749539A1 (en) 2010-07-29
AU2010206840B2 (en) 2015-02-05
AU2010206840A1 (en) 2011-07-21
JP2016138140A (ja) 2016-08-04
JP2021185191A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
JP5766124B2 (ja) 炎症性疾患および自己免疫疾患の処置の組成物および方法
CN100556450C (zh) Il-18抑制剂在治疗或预防脓毒症中的应用
KR102777151B1 (ko) 인터루킨-2의 부분 효능제
KR100607609B1 (ko) Ｉｌ-2 선택성 작용제 및 길항제
Gillespie et al. Interleukin-18: perspectives on the newest interleukin
SK288032B6 (sk) Use of IL-18 inhibitors for manufacture of medicament for treatment and/or prevention of alcoholic hepatitis
US20110177065A1 (en) Methods of treating/preventing inflammation using combination of il-1 antagonist and il-18 binding protein
KR20230060514A (ko) 인터루킨-2 뮤테인 및 이의 용도
AU2002309887B2 (en) Use of IL-18 inhibitors for the treatment or prevention of sepsis
HK1066723B (en) Use of il-18 inhibitors for the treatment or prevention of sepsis
Nolan Paul J. Fairchild, Masahide Tone, Victoria Strong
AU2002309887A1 (en) Use of IL-18 inhibitors for the treatment or prevention of sepsis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150422

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150616

R150 Certificate of patent or registration of utility model

Ref document number: 5766124

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250